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Abstract
A label-free biosensor is developed for the determination of plasma-based Aβ1–42 biomarker in Alzheimer’s disease (AD). The
platform is based on highly conductive dual-layer of graphene and electrochemically reduced graphene oxide (rGO). The
modification of dual-layer with 1-pyrenebutyric acid N-hydroxysuccinimide ester (Pyr-NHS) is achieved to facilitate immobi-
lization of H31L21 antibody. The effect of these modifications were studied with morphological, spectral and electrochemical
techniques. The response of the biosensor was evaluated using differential pulse voltammetry (DPV). The data was acquired at a
working potential of ~ 180 mV and a scan rate of 50mV s−1. A low limit of detection (LOD) of 2.398 pM is achieved over a wide
linear range from 11 pM to 55 nM. The biosensor exhibits excellent specificity over Aβ1–40 and ApoE ε4 interfering species.
Thus, it provides a viable tool for electrochemical determination of Aβ1–42. Spiked human and mice plasmas were used for the
successful validation of the sensing platform in bio-fluidic samples. The results obtained from mice plasma analysis concurred
with the immunohistochemistry (IHC) and magnetic resonance imaging (MRI) data obtained from brain analysis.
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Introduction
The current trend in the realm of medical science is to inves-
tigate the molecular basis of ailments as opposed to following
a symptomatic approach. This has prompted remarkable im-
provements in research for chronic ailments such as
Alzheimer’s disease (AD). Abnormal levels of certain bio-
markers in bio-fluids have been associated with AD
progression [1]. One such biomarker is beta-amyloid (Aβ)
peptide consisting of 40 and 42 amino acids, namely Aβ1–40
and Aβ1–42. Their abnormal levels in bio-fluids have been
correlated with amyloid pathology in AD-affected brain [2].
The continuous monitoring of Aβ levels could provide aid in
early diagnosis, before the onset of symptoms [3]. As a result,
several platforms including enzyme-linked immunosorbent
assay (ELISA) [4], surface-enhanced spectroscopy (SERS)
[5], surface plasmon resonance (SPR) [6], electrochemical
sensors [7–9] and field effect transistors [10] have been devel-
oped. Among these, electrochemical sensors are most attrac-
tive and, therefore, widely preferred. This is attributed to var-
iousmerits such as high sensitivity [3], possibility of label-free
sensing, portability [11], simplicity of apparatus and easy han-
dling [9]. However, electrochemical platforms developed for
Aβ1–42 detection have shown various limitations. These in-
clude lack of bio-fluid analysis, low sensitivity and non-
specific bindings particularly with Aβ1–40 [12].
An interdigitated microelectrode system was recently de-
veloped for the detection of Aβ1–42. The electrode was used
alongside a signal cancellation and amplification processing
system (SCAP) [3]. The platform was validated with mice
plasma samples. Despite excellent sensitivity, use of an
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additional SCAP system makes the platform more complex
and expensive. The specificity of the sensor is also question-
able towards Aβ1–42 in the presence of interfering Aβ1–40 and
ApoE species [13]. Another biosensor based on gold (Au)
electrode and mercaptopropionic acid self-assembled mono-
layer (SAM) reported high sensitivity [2]. However,
the platform failed to depict specificity against any interfering
species present in the complex bio-fluids. With Aβ1–42/Aβ1–
40 ratios gaining interest as a potential biomarker, reliable
detection of individual biomarker is more important than ever
[14, 15]. In addition, deposition of Aβ1–42 starts earlier com-
pared with Aβ1–40 during AD progression [16]. The interfer-
ence with ApoE ε4 species can also prompt false results when
analysing Aβ1–42 in patients’ samples. This is due to the fact
that ApoE ε4 can be present in up to 10,000-fold excess in
human plasma [17]. Therefore, specific determination of Aβ
biomarkers is an important prerequisite for bio-fluid analysis
and understanding AD progression.
Graphene is a widely investigated material due to its re-
markable properties such as high conductivity, biocompatibil-
ity, ease of surface functionalization [18], large surface to
volume ratio and low environmental impact [19]. Graphene-
based biosensors can detect extremely low concentration of
biomarkers [1]. This is attributed to the fact that presence or
absence of a very few analyte molecules can trigger a recog-
nizable change in electrical properties of graphene. Another
material which is widely preferred for biosensors is reduced
graphene oxide (rGO). It has structural similarities to
graphene with large number of electroactive sites providing
highly sensitive material for sensing [18]. Most of the
graphene-based biosensors are based on either only graphene
[20] or only rGO [21]. A combination of the two materials for
the detection of protein biomarkers is yet to be explored. The
conductivity of rGO on graphene is much higher than on other
materials such as carbon [22]. Coupling of rGO and graphene
provides high conductivity with large number of available
active sites which can be useful for biosensing. The rGO sur-
face can be chemically functionalized to anchor antibodies on
the surface [23] which can be achieved by covalent or non-
covalent modifications. The covalent modification may dam-
age and degrade the properties of rGO [24]. Therefore, non-
covalent modification methods are a preferred choice. 1-
Pyrenebutyric acid N-hydroxysuccinimide ester (Pyr- NHS)
is a bi-functional molecule which binds non-covalently to
graphene and carbon surfaces [25, 26]. It promotes strong
immobilization of antibodies without any adverse effect on
the underlying structure. This has shown to improve sensitiv-
ity for detection of clusterin, another well-known biomarker of
AD [25]. Thus, Pyr-NHS is an excellent linker for the immo-
bilization of probes on the graphene biosensors.
In the present work, graphene/rGO dual-layer screen-
printed electrode (SPE) is developed for rapid, label-free and
reliable detection of Aβ1–42. Higher redox current is observed
for dual-layer SPE, confirming its improved sensitivity com-
pared with only graphene and graphene/GO SPE. The immo-
bilization of H31L21 antibody achieved via Pyr-NHS leads to
high specificity of the biosensor towards Aβ1–42 peptides
without damaging underlying rGO structure. The interaction
of Pyr-NHS with rGO on a dual-layer surface is reported for
the first time. The platform shows wide linear dynamic range
with low detection limit. To the best of our knowledge, this is
the first report of a biosensor depicting specificity against
Aβ1–40 and ApoE ε4 interfering species as well as high sen-
sitivity. The biosensor has been successfully validated with
both spiked human and mice plasma samples. Detailed com-
parison of dual-layer SPE over the existing label-free biosen-
sors are made in Table 1.
Experimental
Reagents and animals
Single-layer graphene oxide dispersion in water was pur-
chased from Graphene Supermarket (USA) (https://
graphene-supermarket.com/). Chemicals such as bovine
serum albumin (BSA), 1-pyrenebutyr ic ac id N -
hydroxysuccinimide ester (Pyr-NHS), phosphate buffered sa-
line (PBS), human plasma, Aβ1–42 peptides, potassium ferri-
cyanide (K3Fe(CN)6) and potassium chloride (KCl) at bio-
chemical grade were purchased from Sigma-Aldrich (Dorset,
UK) (https://www.sigmaaldrich.com/united-kingdom.html).
Aβ1–42 antibody (H31L21), 4′,6-Diamidino-2-Phenylindole
(DAPI) and Alexa Fluor 546 goat anti-rabbit secondary anti-
body were provided by Thermo Fisher Scientific (https://
www.thermofisher.com/uk/en/home.html). Aβ1–40 and
ApoE ε4 peptides were obtained from Tocris (UK) (https://
www.tocris.com/). Paraformaldehyde (PFA) was purchased
from Merck (Spain) (https://www.merckgroup.com/es-es).
Sucrose , Tri ton X-100 and Eppendorf® LoBind
Microcentrifuge Tubes were obtained from Sigma-Aldrich
(Spain) (https://www.sigmaaldrich.com/spain.html). Normal
Goat Serum (NGS) and Vectashield H-1200 were provided
by Vector Laboratories (Spain) (https://vectorlabs.com/).
Microvette® CB 300 K2E tubes were obtained from
Sarstedt (Spain) (https://www.sarstedt.com/en/home/).
Blood and brain samples were obtained from 9 and
12 months old wild-type (WT) and transgenic (Tg) animals
of the strain B6.Cg-Tg (APPswe/PSEN1dE9) 85Dbo/Mmjax,
Lab Stock# 005864. All the experiments related to the animals
were performed in the Centro de Investigación Biomédica en
Red Enfermedades Neurodegenerativas (CIBERNED), Spain.
The ethical approval was provided by the “Ethics Committee
for Animal Experimentat ion” of the Inst i tuto de
Investigaciones Biomédicas (CSIC-UAM) and experiments
were carried out in accordance with European Communities
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Council Directive (2010/63/EEC) and National regulations
(Normative 53/2013).
Plasma studies with biosensors were performed in the
University of Plymouth, UK, with approval of Local Ethics
Committee.
Apparatus
Graphene-modified SPEs and μStat potentiostat were provid-
ed by Metrohm DropSens (UK). The electrode had graphene
as working, carbon as an auxiliary and silver as a reference
electrode. Electrochemical cyclic voltammetry (CV) and dif-
ferential pulse voltammetry (DPV) measurements were per-
formed at room temperature with a μStat potentiostat. The
experiments were controlled using DropView 8400 2.0 soft-
ware. The μStat cable connector (ref. DRP-CAST) was used
as an interface between the potentiostat and SPEs.
Raman spectra were obtained using XPLORA HORIBA
system and Olympus BX41 microscope. The system used a
532-nm laser source, power of 100 mW, × 100 objective lens, a
scan range of 1100 to 2000 cm−1 and an exposure time of 5–60 s.
Immunofluorescence data was collected using a Nikon
Eclipse 90i microscope using Plan APO 4x objective,
equipped with Nikon DS-Fi1 digital camera. It was connected
to Nis-Elements software (Madrid, Spain).
Magnetic resonance imaging (MRI) was performed on a
Bruker Pharmascan Biospect system (Bruker Medical Gmbh,
Ettlingen, Germany). The system was equipped with a 7.0-T
horizontal-bore superconducting magnet, 1H receive-only
mouse brain surface coil and volume transmission coil and a
Bruker gradient insert (maximum intensity 36G cm−1). All data
was acquired using a Hewlett-Packard console running on
Paravision 5.1 software (Bruker Medical Gmbh, Germany).
Sensor with monitor system (SA Instruments, Stony Brook,
NY) was used to measure the rate and depth of respiration.
The Thermo Scientific™ Nexsa™ system was used for
carrying out the X-ray photoelectron spectrum (XPS) analysis.
The morphological analysis was done with JEOL 6610 LV
scanning electronmicrscope (SEM) fromOxford Instruments.
Fabrication of biosensor
The graphene/rGO dual-layer SPE was prepared using the
protocol mentioned in our previous work [18]. Briefly, an
aqueous solution of 0.15 mg mL−1 GO was prepared in de-
ionized (DI) water. The solution was then carefully drop
casted onto the surface and dried for 2 h at room temperature.
This promotes strong bond formation of GO on graphene
SPE. After that, the SPE was washed 3 times with DI water.
GO layer was then electrochemically reduced in 10
mM K3[Fe(CN)6] containing 1 M KCl solution by one CV
cycle. A scan rate of 100 mV s−1 was applied, and potential
was varied between 0.5 and -1.5 V [18]. In the next step, theTa
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dual-layer SPE was incubated in 5 mM Pyr-NHS (in metha-
nol) for 2 h at room temperature. Subsequently, it was incu-
bated overnight (16 h) in 20 μg mL−1 of Aβ1–42 antibody
(H31L21) at 4 °C. Then, electrodes were rinsed with PBS to
remove any unbound antibody. This was followed by
blocking of the surface with 2% BSA (in PBS) for 2 h at room
temperature. The schematic representation of the fabrication
process is described in Fig. 1.
Interaction of Aβ1–42 with the sensor
The desired dilutions of Aβ1–42 peptides (0.2 pM to 55 nM)
were freshly prepared in PBS by sonication for 2 min. The
prepared peptides were kept on ice during the experiments to
avoid their aggregation. Then, 20 μL of solution was drop
casted onto the modified SPE and incubated at room temper-
ature for 60 min. After that, the sensor was washed 3 times
before the measurements to remove any unbound peptide. The
measurement time for one sensor is approximately 3–4 min.
Blood sampling method
Blood was drawn by submandibular bleedingmethods using a
sterile blood lancet [29]. The blood droplets were collected by
Microvette® CB 300 K2E tubes. A novel standardized meth-
od of blood extraction and purification protocol was devel-
oped to obtain non-haemolytic plasma samples from rodents.
It consisted of two centrifuge steps. The first centrifuge step
(1500 ×g for 10 min at 15 °C) was performed soon after the
blood collection, to separate the plasma fraction from red
blood cells and buffy coat. Then, the plasma fraction was
collected in Eppendorf® LoBind Microcentrifuge Tubes and
directly placed on ice. The second centrifuge step (3500 ×g for
10 min at 4 °C) was carried out to separate additional red
blood cell debris. Finally, the plasma was divided in aliquots
and stored at − 80 °C for long-term preservation.
Plasma sample analysis
Dual-layer SPE was validated with both mice and human
plasma. The plasma from human was spiked with desired
concentration of Aβ1–42. Then, 20 μl of spiked plasma was
drop casted on to the biosensors for 60 min. Mice plasma
samples were analysed in a similar way without any
pretreatment.
Electrochemical detection
All the measurements were carried out in an electrolyte solu-
tion containing 10 mM potassium ferricyanide solution with
1 M KCl as the supporting electrolyte. CV was recorded from
− 0.2 to + 0.5 V potential and 0.05 V s−1 scan rate without the
application of any preconditioning potential or accumulation
time. For DPV, potential was measured from − 0.15 to +
0.45 V with a step potential of 0.01 V, pulse amplitude of
0.05 V, pulse period of 0.4 s and a scan rate of 0.05 V s−1.
Immunohistochemistry (IHC)
Double immunofluorescence analysis was performed with
brain sections of animals, obtained as previously described
[30]. Briefly, animals were anesthetized followed by
transcardial perfusion. After this, brains were extracted and
postfixed with 4% PFA and 30% sucrose solution overnight
at 4 °C. Subsequently, 30 μm coronal section were obtained
using a cryostat. The selected free floating cortical-
hippocampal section was blocked in 0.1 M phosphate buffer
(PB) containing 3% NGS and 0.1% Triton X-100 for 1 h at
room temperature. It was then incubated with Aβ1–42 primary
antibody (H31L21), overnight at 4 °C. Several washes were
performed in 0.1 M PB containing 0.1% Triton X-100. Then,
the sections were incubated for 1 h with a secondary antibody,
Alexa Fluor 546 goat anti-rabbit. Nuclei staining was per-
formed using DAPI. Finally, the brain sections were mounted
Fig. 1 Schematic representation
of the electrochemical system for
detection of Aβ1–42: a graphene/
rGO SPE-modified with linker
(b), antibody (c), BSA (d) and
Aβ1–42 peptide (e)
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with Vectashield H-1200, and fluorescence microscope im-
ages were performed. The images were processed by ImageJ
software using stitching method [31].
Results and discussion
Characterization of the biosensor
The Raman spectra of graphene and graphene/rGO SPE are
shown in Fig. 2. In case of graphene (blue), there is a weak
peak around 1346 cm−1 and a strong peak around 1574 cm−1.
These can be attributed to the D and G band vibrations of
graphene with intensity ratio of D to G band (ID/IG) equal to
0.1. Further, in case of graphene/rGO (black), wider peaks are
observed around 1346 cm−1 and around 1574 cm−1. Here,
intensity of D band is slightly higher than G band, resulting
in a higher ID/IG ratio of 1.05. The ratio ID/IG indicates average
distance between defective sites. It increases when the oxygen
functionalities onGO are partly removed with electrochemical
reduction [32].
The CVof graphene and graphene/rGO dual-layer SPEwere
recorded from − 0.2 to + 0.5 V at a scan rate of 50 mV s−1 in
10mM [Fe(CN)6]
3−/4− and 1MKCl. The data was acquired at a
working potential of 118 mV. Figure 3a shows a comparison in
the voltammograms of graphene (blue), graphene/GO (red) and
graphene/rGO dual-layer SPE (black). The modification of
graphene with GO leads to a decrease in peak current. This is
attributed to the long-range broken conjugated network of GO
due to a large number of oxygen functional groups.
Electrochemical reduction of GO leads to the formation of
graphene/rGO dual-layer with higher peak currents compared
with only graphene and graphene/GO-modified SPE. This is
due to a combination of inherited electroactive sites from rGO
and high conductivity of graphene [18].
For the fabrication of biosensor, voltammograms were re-
corded after each surface modification step. This includes
graphene/rGO (blue), linker (red), antibody (black) and BSA
(purple) as shown in Fig. 3b. The data was acquired at a
working potential of 118 mV. It exhibit details relating to
the kinetics of charge transfer of the redox probe [Fe(CN)6]
3
− from solution to the electrode. This provides information
about the interfacial properties of different layers on the sur-
face. Assembly of linker decreases the anodic peak current
(Ipa) from 281.033 to 168.628 μA. This is due to an increase
in the electron transfer resistance as it acquires available
electroactive sites on rGO. The pyrene moiety binds to the
rGO surface via non-covalent bonding (π-π interaction),
whereas ester group forms an amide bond (covalent bonding)
with the antibody [25]. The Ipa increases to 214.987 μA after
the immobilization of antibody. This is attributed to the pres-
ence of free NH3+ groups (epsilon amines) present on the
antibody. These groups accelerate electron transfer between
electrode and [Fe(CN)6]
3−/4- system. Immobilization of BSA
decreases the Ipa to 199.534 μA as it acquires free functional
groups on the surface. This minimizes the chances of non-
specific binding.
Scan rate studies (10 to 200 mV s−1) of the modified SPE
were performed to study redox process taking place at the
surface. Peak to peak separation was found to be dependent
on the scan rate indicating a quasi-reversible process. Both
cathodic and anodic peak currents increase with an increment
in scan rate (Fig. 4a). A linear correlation (R2 = 0.99) was
obtained for current versus square root of scan rate (Fig. 4b).
This is attributed to surface controlled diffusion of [Fe(CN)6]
3
−/4- with no surface adsorption and is an important requirement
for electrochemical biosensors [18]. Randles-Sevcik [25]
equation was used for calculating the diffusion coefficient of
the redox couple:
Ip ¼ 2  69 105A
ffiffiffiffi
D
p
ffiffiffi
n
p 3 ffiffiffi
υ
p
C0 ð1Þ
where Ip is peak current of the electrode (in Ampere), A is the
surface area in cm2 (0.126 cm2), D stands for the diffusion
coefficient in cm2 s−1, n denotes the number of transferred
electrons (n = 1), υ denotes the scan rate (V s−1) and C0 is
the concentration of the redox couple (10 mM [Fe(CN)6]
3−/4
−). The value of D was found to be 1.414× 10−6 cm2 s−1 which
is in close agreement with the value of 7.26 × 10−6 cm2 s−1in
the literature [33].
The heterogeneous electron transfer rate constant (Ks) was
calculated for the modified SPE using the Lavrion model:
Ks ¼ mnFυ
RT
ð2Þ
where m is peak to peak separation (0.12 V), n is number of
transferred electrons (1), F is the Faraday constant
(96,485.34 C mol−1), υ denotes scan rate (V s−1), R is
Fig. 2 Raman spectra of graphene (blue) and graphene/rGO (black) dual-
layer SPE
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universal gas constant (8.314 J mol−1 K−1) and T is absolute
temperature (298K). Value of Ks was calculated to be 0.23 s
−1
at a scan rate of 50mV s−1. This indicates fast electron transfer
at the surface of SPE due to large electroactive sites and high
conductivity of dual-layer.
Optimization of sensor parameters
The following parameters were optimized: (a) incubation time
of antibody and (b) concentration of linker; respective data
and figures are given in the electronic supporting material.
The following experimental conditions were found to give
best results: (a) concentration of linker, 5 mM, and (b) incu-
bation time of antibody, 16 h.
Analytical performance of the biosensor
Under optimized condition, sensitivity of the biosensor was
evaluated against a wide range of concentration from 0.2 pM
to 55 nM using DPV. The results were acquired at a working
potential of ~ 180 mV and a scan rate of 50 mV s−1. The
current output of biosensor is shown as a function of different
concentrations of Aβ1–42 in Fig. 5a. The peak current
decreased with the increase in concentration. The calibration
plot of normalized current (IC/Iblank) versus concentrations (in
pM) is shown in Fig. 5b with a linear regression coefficient
(R2 = 0.97). The error bars were calculated based on 3 repli-
cates of each experiment. The LOD was calculated as
2.398 pM using the following equation:
LOD ¼ 3:3* SD=SLð Þ ð3Þ
where SD is standard deviation of the normalized peak current
value of lowest detectable concentration and SL is the slope of
calibration plot. The excellent sensing response can be attrib-
uted to the sensitive structure of the biosensor. Graphene pro-
vides good electrocatalytic activity and electrochemical inert-
ness [18], and rGO provides large electroactive sites. Pyr-
NHS shows strong π-π interaction with the graphene/rGO
dual-layer due to hydrophobic pyrenyl moiety base.
Bioactive ester (NHS) group forms strong amide bond with
the H31L21 antibody [25] resulting in a target-specific plat-
form. However, fabrication process of the biosensor involves
long incubation hours, particularly for antibody immobiliza-
tion step. In addition, orientation of the antibodies on the sur-
face is difficult to control and can reduce the capture efficiency
[34].
Fig. 3 Cyclic voltammograms for
the modification of SPE with a
graphene/rGO (a), graphene (b)
and graphene/GO (c); b graphene/
rGO (a), antibody (b), BSA (c)
and linker (d), and the CV was
taken in 1 M PBS containing
10 mM [Fe(CN)6]
3− and 1 M KCl
solution at a scan rate of
50 mV s−1
Fig. 4 Scan rate studies of
modified SPE a voltammograms
under varying scan rates a-i (10,
25, 50, 75, 100, 125, 150, 175 and
200 mV s−1); b anodic (Ipa) and
cathodic (Ipc) peak currents ver-
sus the square root of corre-
sponding scan rate
Microchim Acta (2020) 187: 288288 Page 6 of 10
Specificity studies
The specificity towards Aβ1–42 was analysed using the DPV
measurements. The modified SPE was incubated in blank
(PBS buffer without protein), 50 pM of Aβ1–42 and 500 nM
of Aβ1–40 and ApoE ε4 biomarkers. The higher concentration
of interfering species was used to ensure the specificity of
sensor in complex fluids such as plasma. The bar graphs ob-
tained from the normalized peak currents were plotted as
shown in Fig. 6. Only Aβ1–42 sample gave a significant de-
crease, whereas the interfering species were almost equivalent
to the blank sample. These results illustrate high specificity of
the biosensor towards the Aβ1–42 species.
Plasma sample analysis
Blood-based analysis of AD biomarkers is emerging as
an alternative to the established strategies [35, 36]. This
is attributed to the fact that blood sampling technique is
less complex and minimally invasive and, therefore, can
be applied to large communities. As a result, the
biosensor was validated with blood plasma (in a series
of two experiments) to check the applicability for bio-
fluid analysis. In the first experiment, human plasma was
spiked with known concentrations (50, 220, 2200 and
16,600 pM) of Aβ1–42. The DPV curves at varying con-
centration of spiked antigen and its calibration plot are
shown in Fig. 7a, b. The sensing platform displayed high
linearity in human plasma (R2 = 0.98).
In the second experiment, plasma samples obtained from 9
and 12-months-old WT and Tg mice were analysed without
any pretreatment. The Tg mouse is an expression of a chime-
ric mouse and human amyloid precursor protein (Mo/
HuAPP695swe). It also overexpresses a mutant human
presenilin 1 (PS1-dE9) gene. Both mutations are associated
with early-onset AD. Therefore, these animals are humanized
models and produce human Aβ peptide species (e.g. Aβ1–42).
These Aβ1–42 species can be detected by specific antibody
that either recognize human or mice sequence or both of them
[37]. For this reason, human Aβ1–42 antibody (H31L21) was
used for validation of mice samples using the biosensor. The
DPV results shown in Fig. 7c display a much larger shift in
peak current for Tg mice as opposed to WT mice. This indi-
cates a higher Aβ1–42 concentration in plasma of Tg mice. An
age-based study was also performed as shown in Fig. 7d. As
seen, a higher normalized current (IC/Iblank) is observed in
case of 12 months in contrast to 9-month-old mice plasma.
This is attributed to the decrease in concentration of Aβ1–42 in
the plasma of older mice with the progression of AD.
However, a larger sample size (> 6) is needed for further
validation of the biosensor before it can be employed for
the determination of patients’ sample.
The immunohistochemistry (IHC) data shows a higher ac-
cumulation of Aβ1–42 in both cortex and hippocampus region.
It increases with age for Tg mice compared with WT mice
(Fig. 8). This increase in Aβ plaques burden leads to decrease
in plasma Aβ1–42 levels observed in Fig. 7 (d) [38]. The cor-
relation in the IHC and sensing data further confirms the reli-
ability of the platform for plasma sample analysis. The mag-
netic resonance imaging (MRI) data of the 12-month-old mice
Fig. 5 Analytical performance of
the biosensor a DPV curves
obtained for the biosensor for
detection of different
concentration of Aβ1–42 from a-h
(0.2, 2, 11, 50, 220, 2200, 16,600
and 55,000 pM); b Calibration
plot representing normalized cur-
rent (IC/Iblank) of DPV data as a
function of Aβ1–42 concentration
on a logarithmic scale (n = 3)
Fig. 6 Specificity of the biosensor for the detection of 50 pM of Aβ1–42
with 500 nM of interfering agents: Aβ1–40 and ApoE ε4
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Fig. 8 IHC data for the
progression of AD pathology: An
increase of human-specific Aβ(1–
42) (red) aggregation in cortex and
hippocampal area; especially in
stratum radiatum (SR), stratum
lacunosum-moleculare (SLM)
and outer portion of the molecular
layer of dentate gyrus (OML) and
the hilus of the dentate gyrus
(DG), from 9 to12-months-old Tg
compared with E littermates.
Cornu ammonis (CA1, CA2,
CA3 and hilus (CA4)) are sub-
field of the hippocampus; nuclei
staining is in blue
Fig. 7 DPV responses from
spiked concentration of Aβ1–42
(50 (a), 220 (b), 2200 (c) and
16,600 (d) pM) in human plasma
(a); calibration plot of normalized
current (IC/Iblank) versus log of
Aβ1–42 concentration (b); DPV
responses for detection of WT (b)
and Tg (c) mice compared with
blank response (a); an age-based
study with the two groups (9 and
12months) of Tg animals (d) (n =
3)
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was collected. It also depicts Aβ plaques accumulation in
cortex and hippocampus area of the brain (electronic
supplementary information Fig. S5).
Conclusion
In summary, graphene/rGO dual-layer SPE was developed for
highly sensitive and label-free detection of Aβ1–42. The im-
mobilization of antibodies was achieved via Pyr-NHS mole-
cule. Its pyrene moiety binds to rGO via non-covalent bond-
ing, and ester group forms strong amide bonds with antibody.
The sensor depicted high specificity towards Aβ1–42 over in-
terfering Aβ1–40 and ApoE ε4 species. It shows excellent
performance for human and mice plasma analysis. Age-
based study of mice samples exhibited a decrease in levels
of Aβ1–42 with the disease progression (from 9 to 12 months
old). This was attributed to the increased Aβ1–42 accumulation
in 12-month-old mice shown by the IHC and MRI studies.
However, the present study has few limitations. Firstly, the
orientation of antibodies on the surface is random which can
decrease the capture efficiency and affect the sensitivity of the
platform. Secondly, fabrication process of the biosensor is
time-consuming due to long incubation hours. Despite this,
use of SPEs makes the fabrication process inexpensive and
less complex with a possibility of mass production on a large
scale. These can also be integrated with point of care devices
to develop routine diagnostic tools for AD. For the future
work, more comprehensive studies will be conducted using
a larger sample size to verify the applicability of biosensor in
identifying different stages of AD.
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